Janssen Halts the Development of Pimodivir for Influenza

 Janssen Halts the Development of Pimodivir for Influenza

Janssen Halts the Development of Pimodivir for Influenza

Shots:

  • The discontinuation is based on pre-planned interim analyses of P-III studies assessing Pimodivir + SOC vs SOC as monothx. in hospitalized & non-hospitalized patients with influenza A
  • The therapy is unlikely to add benefits in hospitalized patients with influenza A. The company will halt both the studies, after consulting with BARDA
  • In 2014, Janssen signed an exclusive license agreement with Vertex for the global development, manufacturing, and commercialization of pimodivir

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Philadelphia Inquirer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post